Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
December 23, 2024 07:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
December 13, 2024 18:15 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved...
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024 16:10 ET
|
Fortress Biotech, Inc.
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
November 04, 2024 07:00 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and...
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
October 15, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies...
Inbiome, developing a new PCR technology capable of simultaneous identification of hundreds of bacterial pathogens in a single test, welcomes Professor Dr. Carl Wittwer to its Advisory Board
September 20, 2024 05:03 ET
|
inbiome
Amsterdam, The Netherlands, September 20, 2024. Inbiome, a pioneer in advanced molecular diagnostics, today announced the appointment of Professor Dr. Carl Wittwer (picture), a global authority in PCR...
Philips announces FDA approval for enhanced LumiGuide guidewire and marks the 1000th patient treated with its breakthrough 3D device guidance technology
September 17, 2024 08:56 ET
|
Royal Philips
Enhanced longer version of Philips LumiGuide Navigation Wire enables US clinicians to visualize a broader range of catheters Internationally recognized vascular surgeon Carlos Timaran, MD, was the...
Bispecific Antibody Drug Conjugates Clinical Trials Insight
September 17, 2024 07:14 ET
|
KuicK Research
Delhi, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The global market for bispecific antibody-drug conjugates (BsADCs) has experienced remarkable expansion, attributed to their revolutionary capabilities in...
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
September 12, 2024 08:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 05, 2024 17:34 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy.